Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMCN6PY)

Drug Name
2-cyano-3-(3,4-dihydroxyphenyl)acrylamide Drug Info
Synonyms
Tyrphostin 46; Tyrphostin A46; AG 99; Tyrphostin B40; 122520-85-8; alpha-Cyano-(3,4-dihydroxy)cinnamide; AG-99; 3,4-Dihydroxy-alpha-cyanocinnamamide; UNII-ARL2OF9022; CHEMBL296407; ARL2OF9022; 118409-59-9; Tyrphostin AG 99; (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; NSC666250; NSC-666250; 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-; (~{E})-3-[3,4-bis(oxidanyl)phenyl]-2-cyano-prop-2-enamide; Tyrphostin AG99; 3,4-Dihydroxy-alpha-cyanocinnamide; NSC 666250; Tocris-0497; Tyrphostin deriv. 40; BiomolKI_000013; AC1NS5AR
Cross-matching ID
PubChem CID
5328768
ChEBI ID
CHEMBL296407
CAS Number
CAS 118409-59-9
TTD Drug ID
D01NTW

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Fanconi anemia pathway 1.89 3.03e-2 36/54 (66.67%) BLM;BRCA1;RPA3;...
Vitamin digestion and absorption 1.83 3.78e-2 17/24 (70.83%) SLC5A6;APOA1;APOB;...
Viral myocarditis -1.77 2.67e-2 53/60 (88.33%) MYH6;EIF4G1;HLA-C;...
Synaptic vesicle cycle -1.77 2.65e-2 63/78 (80.77%) DNM2;NSF;AP2A2;...
Asthma -1.78 2.63e-2 25/31 (80.65%) RNASE3;FCER1G;HLA-DPB1;...
Systemic lupus erythematosus -1.81 2.02e-2 45/135 (33.33%) HLA-DRA;CTSG;C1QA;...
Cardiac muscle contraction -1.82 2.09e-2 64/87 (73.56%) CACNG5;MYH6;SLC9A7;...
Allograft rejection -1.83 1.81e-2 32/38 (84.21%) HLA-DPB1;TNF;FASLG;...
Staphylococcus aureus infection -1.83 1.86e-2 72/95 (75.79%) KRT14;HLA-DPB1;ITGB2;...
Antigen processing and presentation -1.85 1.69e-2 60/78 (76.92%) CD4;CALR;HLA-C;...
Th1 and Th2 cell differentiation -1.87 1.45e-2 80/92 (86.96%) CD3D;STAT1;HLA-DPB1;...
Dilated cardiomyopathy -1.95 1.08e-2 86/96 (89.58%) ATP2A2;ADCY2;MYBPC3;...
Hypertrophic cardiomyopathy -1.95 1.45e-2 81/90 (90%) ATP2A2;MYBPC3;CACNB4;...
Graft-versus-host disease -1.96 1.45e-2 32/42 (76.19%) HLA-DPB1;KIR2DL1;TNF;...
Phagosome -2.00 0.00e+0 118/152 (77.63%) ATP6V0E2;THBS4;ITGA5;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H, 24H